A former diabetes trial drug shows potential to treat Parkinson’s disease in the near future, according to recent research. The drug NLX-112, originally developed to address dyskinesia caused by long-term levodopa-based medication use in Parkinson’s patients, also demonstrates potential in improving motor symptoms associated with the condition. Parkinson’s UK believes that NLX-112 could pave the way for a new, comprehensive treatment approach by 2030. The positive results of a phase 2a trial conducted by bio-pharmaceutical company Neurolixis are currently being presented at the World Parkinson’s Congress.
“The positive effect seen on both dyskinesia and movement symptoms could make NLX-112 an important, dual efficacy therapy, thanks to its novel neurochemical mechanism, distinct to that of current medications for Parkinson’s.” – Adrian Newman-Tancredi, Neurolixis
In the trial, NLX-112 demonstrated a significant reduction in movement symptoms, such as slowness, stiffness, and tremor, among participants. Experts believe that the medication is comparable in performance to the current best-available drugs for these symptoms at low doses. Adrian Newman-Tancredi, co-founder, president, and chief executive of Neurolixis, expressed optimism about the drug’s potential and emphasized the need for larger studies. If future trials are successful, NLX-112 could be accessible by 2030.
Currently, most Parkinson’s medications work by increasing or mimicking dopamine, a neurochemical in the brain. While effective in the early stages, these therapies, like levodopa, become less effective over time and often lead to dyskinesia in Parkinson’s patients. NLX-112, with its unique serotonergic pathway mechanism, presents a different approach to Parkinson’s treatment. Early results from the phase 2a trial have shown clear anti-dyskinesia effects that improve over time and suggest positive outcomes for Parkinson’s symptoms as well.
Dr. Arthur Roach, director of the Parkinson’s Virtual Biotech at Parkinson’s UK, highlighted the potential of NLX-112 in managing movement symptoms and emphasized the importance of the ongoing partnership between Parkinson’s UK, the Michael J Fox Foundation, and Neurolixis. The promising findings reinforce the need for expedited research and development to deliver new treatments for Parkinson’s in the coming years.
The phase 2a trial included 26 participants with Parkinson’s and dyskinesia, and the results showed that NLX-112 was well-tolerated and safe. Further studies are needed to investigate its efficacy on a larger scale.
Katharina Klapper, director of clinical research at the Michael J Fox Foundation, expressed enthusiasm for the early results and their potential impact on treating levodopa-induced dyskinesia. Collaboration and innovation in clinical research are crucial to advancing Parkinson’s treatments and improving the lives of patients and their families.
Denial of responsibility! TechCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Jessica Irvine is a tech enthusiast specializing in gadgets. From smart home devices to cutting-edge electronics, Jessica explores the world of consumer tech, offering readers comprehensive reviews, hands-on experiences, and expert insights into the coolest and most innovative gadgets on the market.
